Menu

Toledo Water Back On After Toxic Scare

Citizens of Ohio’s fourth-largest city can drink from the tap again, but the root causes of the Lake Erie algal blooms that shut off the flow for two days remain.

Aug 5, 2014
Bob Grant

This satellite image shows the algal bloom that occured in Lake Erie in 2011.NASA EARTH OBSERVATORYAfter a parched weekend for more than 400,000 people in and around Toledo, Ohio, safe drinking water is again flowing from their taps, according to city officials. The two-day drinking water ban that started on Saturday (August 2) was prompted by high levels of microcystin—a toxin that can sicken people and kill pets—in Lake Erie, from which water is extracted and processed for municipal supplies. A toxic peptide, microcystin is produced by cyanobacteria, which tend to bloom in the shallow lake during summer months, thanks to phosphorus runoff from farms, fertilized lawns, cattle feedlots, and leaking septic systems.

“Our water is safe,” Toledo Mayor D. Michael Collins told reporters on Monday (August 4) before drinking a glass of tap water at a press conference to announce the lifting of the ban.

Officials still cautioned residents to cut back on non-essential water use, and urged home and business owners to flush their lines to clear any residual toxins in the lines.

Although algal blooms occur in Lake Erie every summer, they became particularly dangerous this year. “Weather conditions made it such that bloom was going right into the water intakes,” Jeffrey Reutter, head of the Ohio Sea Grant research lab, told the Associated Press. This was compounded by the fact that phosphorus levels in the lake have been climbing since the mid-1990s. “We’re right back to where we were in the ’70s,” when Lake Erie was considered heavily polluted, Reutter added.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.